Analysts Set Liquidia Corporation (NASDAQ:LQDA) PT at $86.18

Shares of Liquidia Corporation (NASDAQ:LQDA) have received an average rating of “Hold” from the eleven brokerages that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $98.0833.

Several research firms have issued reports on LQDA. Raymond James Financial reiterated a “strong-buy” rating and issued a $106.00 target price on shares of Liquidia in a research note on Thursday. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. Zacks Research cut shares of Liquidia from a “strong-buy” rating to a “hold” rating in a report on Thursday. Wells Fargo & Company increased their price objective on Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Oppenheimer set a $75.00 price objective on Liquidia in a research note on Friday, June 5th.

Liquidia Trading Up 3.2%

Shares of LQDA opened at $74.44 on Friday. Liquidia has a twelve month low of $21.15 and a twelve month high of $93.61. The stock has a market cap of $6.66 billion, a PE ratio of 54.34 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The business’s 50-day moving average price is $78.67 and its 200-day moving average price is $55.13.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. Liquidia’s revenue was up 1842.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.49) earnings per share. On average, equities analysts forecast that Liquidia will post 2.57 EPS for the current fiscal year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

Insider Transactions at Liquidia

In other news, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the transaction, the director owned 1,176,184 shares of the company’s stock, valued at approximately $82,838,639.12. The trade was a 17.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul B. Manning sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the completion of the transaction, the director owned 716,311 shares in the company, valued at approximately $45,779,436.01. This trade represents a 21.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,756,861 shares of company stock worth $122,981,112 over the last 90 days. Corporate insiders own 25.60% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP raised its position in Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after purchasing an additional 24,555 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Liquidia by 63.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new position in shares of Liquidia in the 4th quarter worth about $709,000. WCG Wealth Advisors LLC boosted its holdings in shares of Liquidia by 98.2% in the 4th quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company’s stock worth $1,877,000 after purchasing an additional 26,957 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Liquidia by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after purchasing an additional 52,671 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).